ER+/HER2 Breast Cancer Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant,

DelveInsight's "ER+/HER2 Breast Cancer - Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the ER+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2 Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Emerging therapies for ER+/HER2 breast cancer-such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171/GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and several others-are anticipated to drive significant growth in the ER+/HER2 breast cancer market in the coming years.

DelveInsight has launched a new report on "ER+/HER2 Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the ER+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2 Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover latest insights into our ER+/HER2- Breast cancer market report https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the ER+/HER2 Breast Cancer Market Report:

*
In 2021, the total number of new breast cancer cases in the United States was 256,431. Among these, postmenopausal breast cancer accounted for 205,145 cases. In the same year, the distribution of breast cancer cases by stage was as follows: 164,116 localized, 74,365 regional, 15,386 distant, and 2,564 with unknown stage. These numbers are expected to rise during the forecast period.

*
Among the various subtypes of the disease (localized and regional), ER+/HER2 represented the largest patient group with 147,977 cases, followed by 24,325 cases of triple-negative breast cancer and 20,271 cases of ER+/HER2+. Conversely, HR/HER2+ had the fewest cases.

*
Key ER+/HER2 Breast Cancer companies such as Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others are evaluating new drugs for ER+/HER2 Breast Cancer to improve the treatment landscape.

*
Promising ER+/HER2 Breast Cancer pipeline therapies in various stages of development include KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others.

Key benefits of the ER+/HER2 Breast Cancer market report:

*
ER+/HER2 Breast Cancer market report covers a descriptive overview and comprehensive insight of the ER+/HER2 Breast Cancer Epidemiology and ER+/HER2 Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

*
The ER+/HER2 Breast Cancer market report provides insights on the current and emerging therapies.

*
ER+/HER2 Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The ER+/HER2 Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the ER+/HER2 Breast Cancer market.

Got queries? Click here to know more about the ER+/HER2 Breast Cancer Market Landscape [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

ER+/HER2 Breast Cancer Overview

Breast cancer arises when abnormal cells in the breast grow and divide uncontrollably, eventually forming a tumor. It usually originates in the ducts or lobules of the breast and may be driven by various growth signals, including hormones.

Hormone receptors are proteins on cancer cells that recognize hormone signals and trigger cell growth. When breast cancer cells respond to estrogen, it's called estrogen receptor-positive (ER+) breast cancer. If they respond to progesterone, it's progesterone receptor-positive (PR+). Cancers that are ER+ and/or PR+ are grouped under hormone receptor-positive (HR+) breast cancer.

Conversely, hormone receptor-negative (HR) breast cancer lacks these receptors and doesn't depend on estrogen or progesterone to grow.

Another important factor is the human epidermal growth factor receptor 2 (HER2), a protein involved in cell growth and repair. HER2-positive (HER2+) breast cancers have high levels of this protein and tend to grow faster and have a higher risk of spreading or returning. HER2 status is identified through testing.

HER2-negative (HER2) breast cancers have low or no HER2 protein expression. These cancers generally grow more slowly and are less likely to spread than HER2+ types. Determining HER2 status is essential for guiding appropriate treatment.

ER+/HER2 Breast Cancer Treatment Market

Estrogen receptor (ER) expression plays a critical role in determining how well hormonal therapies will work, as the majority of breast cancers are hormone-dependent and ER-positive. Treatment options for patients with early-stage, advanced, or metastatic breast cancer include various anti-estrogenic therapies such as selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs).

Current clinical research is increasingly focused on enhancing the effectiveness of these therapies by combining them with targeted agents that inhibit the PI3K/AKT/mTOR signaling pathway or the CDK4/6 pathway, which controls the G1/S cell cycle checkpoint. These combinations are being explored particularly for hormone receptor-positive breast cancer patients who have experienced disease progression or recurrence.

Discover how the ER+/HER2- Breast cancer treatment market [https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] is growing

ER+/HER2 Breast Cancer Market Outlook

Breast cancer ranks as the second most commonly diagnosed cancer worldwide, with estrogen receptor-positive (ER+) breast cancer being the most frequent subtype. Roughly two-thirds of all breast cancer cases are hormone receptor-positive (HR+), predominantly ER+, meaning they are fueled by estrogen, which promotes tumor growth.

The stage at diagnosis greatly influences treatment strategy. In Stages I to III, surgery is typically the first-line treatment, often followed by radiation. Depending on hormone receptor and HER2 status, additional therapies may include chemotherapy, hormone therapy (such as tamoxifen or aromatase inhibitors), and HER2-targeted drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta). For early-stage HR+ breast cancer (Stage I), hormone therapy is usually sufficient, while larger tumors might also require chemotherapy. HER2-positive tumors are treated with HER2-directed therapies.

In Stage II, systemic treatments-either before (neoadjuvant) or after surgery (adjuvant)-are commonly used. Neoadjuvant therapies can reduce tumor size to allow for breast-conserving surgery. Stage III cancers often need neoadjuvant chemotherapy, and HER2-targeted therapies are added when appropriate.

Treatment options include tamoxifen, aromatase inhibitors (letrozole, anastrozole, exemestane), luteinizing hormone-releasing hormone analogs (goserelin, leuprolide), and fulvestrant, especially in cases of resistance. Patients typically receive sequential hormone therapies until resistance emerges, at which point chemotherapy is considered.

The ER+/HER2 breast cancer pipeline features a number of promising therapies in mid-to-late stages of development. Companies like Radius Pharmaceuticals (Elacestrant), AstraZeneca (Camizestrant), and Roche (Giredestrant) are actively developing innovative treatments that could transform the therapeutic landscape in the near future.

Explore more about ER+/HER2- Breast cancer market [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

ER+/HER2 Breast Cancer Marketed Drugs:

*
KISQALI (ribociclib): Novartis

*
IBRANCE (palbociclib): Pfizer

*
AFINITOR (everolimus): Novartis

*
LYNPARZA (olaparib): AstraZeneca

ER+/HER2 Breast Cancer Emerging Drugs:

*
Elacestrant: Radius Pharmaceuticals

*
Giredestrant (RG6171, GDC-9545): Roche

*
Camizestrant (AZD9833): AstraZeneca

*
LY3484356 (imlunestrant): Eli Lilly

*
Lerociclib (EQ132): EQRx

Discover which ER+/HER2- Breast cancer drugs [https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] will boost the market in the upcoming years

Scope of the ER+/HER2 Breast Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key ER+/HER2 Breast Cancer Companies: Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others

*
Key ER+/HER2 Breast Cancer Therapies: KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others

*
ER+/HER2 Breast Cancer Therapeutic Assessment: ER+/HER2 Breast Cancer current marketed and ER+/HER2 Breast Cancer emerging therapies

*
ER+/HER2 Breast Cancer Market Dynamics: ER+/HER2 Breast Cancer market drivers and ER+/HER2 Breast Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
ER+/HER2 Breast Cancer Unmet Needs, KOL's views, Analyst's views, ER+/HER2 Breast Cancer Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. ER+/HER2 Breast Cancer Patient Share (%) Overview at a Glance

5. ER+/HER2 Breast Cancer Market Overview at a Glance

6. ER+/HER2 Breast Cancer Disease Background and Overview

7. ER+/HER2 Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of ER+/HER2 Breast Cancer

9. ER+/HER2 Breast Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. ER+/HER2 Breast Cancer Emerging Therapies

12. ER+/HER2 Breast Cancer Market Outlook

13. Country-Wise ER+/HER2 Breast Cancer Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. ER+/HER2 Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

ER+/HER2 Breast Cancer Pipeline Insights, DelveInsight

"ER+/HER2 Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the ER+/HER2 Breast Cancer market. A detailed picture of the ER+/HER2 Breast Cancer pipeline landscape is provided, which includes the disease overview and ER+/HER2 Breast Cancer treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=erher2-breast-cancer-market-epidemiology-pipeline-products-companies-working-delveinsight-kisqali-ribociclib-ibrance-palbociclib-afinitor-everolimus-lynparza-olaparib-elacestrant]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.